12:00 AM
 | 
Jul 09, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor activator of NF-κB ligand (RANKL; TNFSF11); macrophage colony-stimulating factor 1 (CSF1; M-CSF)

Musculoskeletal disease

INDICATION: Osteoporosis

Cell culture and rodent studies suggest indazole-based inhibitors of RANKL signaling could help treat osteoporosis. Chemical synthesis and in vitro testing of indazole carboxylic acid analogs identified a compound that inhibited RANKL-induced NF-κB signaling in mouse macrophages and decreased RANKL- and CSF1-induced osteoclastogenesis in rat...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >